BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28657220)

  • 1. Prognostic models for locally advanced cervical cancer: external validation of the published models.
    Lora D; Gómez de la Cámara A; Fernández SP; Enríquez de Salamanca R; Gómez JFPR
    J Gynecol Oncol; 2017 Sep; 28(5):e58. PubMed ID: 28657220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-treatment MRI minimum apparent diffusion coefficient value is a potential prognostic imaging biomarker in cervical cancer patients treated with definitive chemoradiation.
    Marconi DG; Fregnani JH; Rossini RR; Netto AK; Lucchesi FR; Tsunoda AT; Kamrava M
    BMC Cancer; 2016 Jul; 16():556. PubMed ID: 27469349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postreatment squamous cell carcinoma antigen as a survival prognostic factor in patients with locally advanced cervical cancer. A Spanish multicenter study. The SEGO Spain-GOG group.
    Benito V; Lubrano A; Pérez-Regadera JF; Torné A; Gil-Moreno A; Tejerizo-Garcia Á; Vergés R; Díaz-Feijoo B;
    Gynecol Oncol; 2021 Aug; 162(2):407-412. PubMed ID: 34119366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
    Chen CC; Wang L; Lin JC; Jan JS
    J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy.
    Rose PG; Java J; Whitney CW; Stehman FB; Lanciano R; Thomas GM; DiSilvestro PA
    J Clin Oncol; 2015 Jul; 33(19):2136-42. PubMed ID: 25732170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic nomogram for overall survival in stage IIB-IVA cervical cancer patients treated with concurrent chemoradiotherapy.
    Tseng JY; Yen MS; Twu NF; Lai CR; Horng HC; Tseng CC; Chao KC; Juang CM
    Am J Obstet Gynecol; 2010 Feb; 202(2):174.e1-7. PubMed ID: 19931041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of R2* obtained from T2*-weighted imaging in predicting the prognosis of advanced cervical squamous carcinoma treated with concurrent chemoradiotherapy.
    Li XS; Fan HX; Fang H; Song YL; Zhou CW
    J Magn Reson Imaging; 2015 Sep; 42(3):681-8. PubMed ID: 25581675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome and toxicity of radical radiotherapy or concurrent Chemoradiotherapy for elderly cervical cancer women.
    Wang W; Hou X; Yan J; Shen J; Lian X; Sun S; Liu Z; Meng Q; Wang D; Zhao M; Qiu J; Hu K; Zhang F
    BMC Cancer; 2017 Aug; 17(1):510. PubMed ID: 28764676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk assessment model for overall survival in patients with locally advanced cervical cancer treated with definitive concurrent chemoradiotherapy.
    Shim SH; Lee SW; Park JY; Kim YS; Kim DY; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2013 Jan; 128(1):54-59. PubMed ID: 23063760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of nedaplatin-based concurrent chemoradiotherapy for FIGO Stage IB2-IVA cervical cancer and its clinical prognostic factors.
    Fujiwara M; Isohashi F; Mabuchi S; Yoshioka Y; Seo Y; Suzuki O; Sumida I; Hayashi K; Kimura T; Ogawa K
    J Radiat Res; 2015 Mar; 56(2):305-14. PubMed ID: 25428244
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
    Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
    Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-free Survival After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
    Zhang Y; Liu L; Zhang K; Su R; Jia H; Qian L; Dong J
    Acad Radiol; 2023 Mar; 30(3):499-508. PubMed ID: 36050264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integration Pattern of Human Papillomavirus Is a Strong Prognostic Factor for Disease-Free Survival After Radiation Therapy in Cervical Cancer Patients.
    Joo J; Shin HJ; Park B; Park SY; Yoo CW; Yoon KA; Kong SY; Kim YJ; Kim SS; Kim JY
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(3):654-661. PubMed ID: 28581408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer.
    Cho O; Chun M; Chang SJ; Oh YT; Noh OK
    Anticancer Res; 2016 Jul; 36(7):3541-7. PubMed ID: 27354621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study.
    Kang S; Nam BH; Park JY; Seo SS; Ryu SY; Kim JW; Kim SC; Park SY; Nam JH
    J Clin Oncol; 2012 Jul; 30(19):2369-74. PubMed ID: 22614984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of chemoradiotherapy in cervical cancer--the Western Australian experience.
    Lim A; Sia S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1431-8. PubMed ID: 21640504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Computed Tomography-Planned High-Dose-Rate Brachytherapy for Treating Uterine Cervical Cancer.
    Zolciak-Siwinska A; Gruszczynska E; Bijok M; Jonska-Gmyrek J; Dabkowski M; Staniaszek J; Michalski W; Kowalczyk A; Milanowska K
    Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):87-92. PubMed ID: 27375169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma.
    Yokoi E; Mabuchi S; Takahashi R; Matsumoto Y; Kuroda H; Kozasa K; Kimura T
    J Gynecol Oncol; 2017 Mar; 28(2):e19. PubMed ID: 28028992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of total lesion glycolysis measured by 18F-FDG PET/CT in patients with locally advanced cervical cancer.
    Hong JH; Jung US; Min KJ; Lee JK; Kim S; Eo JS
    Nucl Med Commun; 2016 Aug; 37(8):843-8. PubMed ID: 27058362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. External validation of a combined PET and MRI radiomics model for prediction of recurrence in cervical cancer patients treated with chemoradiotherapy.
    Lucia F; Visvikis D; Vallières M; Desseroit MC; Miranda O; Robin P; Bonaffini PA; Alfieri J; Masson I; Mervoyer A; Reinhold C; Pradier O; Hatt M; Schick U
    Eur J Nucl Med Mol Imaging; 2019 Apr; 46(4):864-877. PubMed ID: 30535746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.